Sugi Predict

Sugi Predict / Compounds / SCHEMBL2401271

SCHEMBL2401271

SCHEMBL2401271

NCC1CN(c2cccc(F)c2N2CCOCC2)C(=O)O1

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 1/20 0.51
▸ GRM2 Q14416 1/20 0.46
▸ MAOA P21397 3/20 0.46
▸ MAOB P27338 9/20 0.44
▸ LMNA P02545 1/20 0.44
▸ PTGS1 P23219 1/20 0.44
▸ CALML3 P27482 1/20 0.44
▸ SDHA P31040 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ P2RX7 Q99572 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2401267 1.00 F10 (0.51) F10GRM2MAOAMAOBLMNA
SCHEMBL5513931 1.00 F10 (0.51) F10GRM2MAOAMAOBLMNA
Hydrochloric Acid SCHEMBL2875195 0.99 F10 (0.50) F10GRM2MAOAMAOBLMNA
Bromide SCHEMBL2863293 0.99 F10 (0.50) F10GRM2MAOAMAOBLMNA
SCHEMBL5123312 0.89 GRM2 (0.46) F10GRM2MAOAMAOBLMNA
SCHEMBL28411961 0.89 GRM2 (0.46) F10GRM2MAOAMAOBLMNA
SCHEMBL2046431 0.89 MAOB (0.46) GRM2MAOAMAOBLMNAPTGS1
SCHEMBL3519370 0.87 GRM2 (0.46) F10GRM2MAOAMAOBCALML3
SCHEMBL3117926 0.86 MAOA (0.47) F10GRM2MAOAMAOBLMNA
SCHEMBL28673556 0.86 F10 (0.51) F10GRM2MAOAMAOBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114505036-A Method and equipment for preparing linezolid 程竹隐 2022-05-17 — — CN claimed
CN-110934880-A Compositions containing mixtures of phenyl oxazolidinone derivatives and uses thereof 黄泳华 2020-03-31 — — CN claimed
US-20170066728-A1 PROCESS FOR THE PREPARATION OF STABLE CRYSTALLINE FORM-I OF LINEZOLID, SUBSTANTIALLY FREE OF RESIDUAL SOLVENT JUBILANT LIFE SCIENCES LTD (IN) 2017-03-09 — — US claimed
EP-2852580-A1 IMPROVED PROCESS FOR THE PREPARATION OF STABLE CRYSTALLINE FORM-I OF LINEZOLID, SUBSTANTIALLY FREE OF RESIDUAL SOLVENT Jubilant Life Sciences Ltd. (IN) 2015-04-01 — — EP claimed
US-20150025236-A1 PROCESS FOR THE PREPARATION OF STABLE CRYSTALLINE FORM-I OF LINEZOLID, SUBSTANTIALLY FREE OF RESIDUAL SOLVENT JUBILANT LIFE SCIENCES LTD (IN) 2015-01-22 — — US claimed
WO-2013111048-A1 IMPROVED PROCESS FOR THE PREPARATION OF STABLE CRYSTALLINE FORM-I OF LINEZOLID, SUBSTANTIALLY FREE OF RESIDUAL SOLVENT JUBILANT LIFE SCIENCES LIMITED (IN) 2013-08-01 — — WO claimed
WO-2011114210-A2 PROCESSES FOR THE PREPARATION OF LINEZOLID JUBILANT LIFE SCIENCES LIMITED (IN) 2011-09-22 — — WO claimed
US-7691889-B2 Antimycobacterial compounds LUPIN LIMITED (IN) 2010-04-06 — — US claimed
EP-1861383-A2 ISOLATED BIS-LINEZOLID, PREPARATION THEREOF, AND ITS USE AS A REFERENCE STANDARD Teva Pharmaceutical Industries Ltd (IL) 2007-12-05 — — EP claimed
US-20060252932-A1 Isolated bis-linezolid, preparation thereof, and its use as a reference standard ENTIRE INTEREST 2006-11-09 — — US claimed
WO-2006091848-A9 ISOLATED BIS-LINEZOLID, PREPARATION THEREOF, AND ITS USE AS A REFERENCE STANDARD TEVA PHARMA (IL) 2006-11-09 — — WO claimed
WO-2006091848-A2 ISOLATED BIS-LINEZOLID, PREPARATION THEREOF, AND ITS USE AS A REFERENCE STANDARD TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2006-08-31 — — WO claimed
US-20050192275-A1 Novel antimycobacterial compounds LUPIN LIMITED (IN) 2005-09-01 — — US claimed
CN-115902018-A Detection method of linezolid isomer 江苏晨牌药业集团股份有限公司 2023-04-04 — — CN disclosed
CN-114505036-A Method and equipment for preparing linezolid 程竹隐 2022-05-17 — — CN disclosed
CN-110183393-B Method for preparing linazolone intermediate 常州沃腾化工科技有限公司 2022-03-11 — — CN disclosed
US-20060111350-A1 Solid forms of linezolid and processes for preparation thereof TEVA PHARMACEUTICALS USA, INC. 2006-05-25 — — US disclosed
EP-1658275-A1 CRYSTALLINE FORM IV OF LINEZOLID Teva Pharmaceutical Industries Ltd (IL) 2006-05-24 — — EP disclosed
WO-2006004922-A1 CRYSTALLINE FORM IV OF LINEZOLID TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2006-01-12 — — WO disclosed
US-20050192275-A1 Novel antimycobacterial compounds LUPIN LIMITED (IN) 2005-09-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170066728-A1 PROCESS FOR THE PREPARATION OF STABLE CRYSTALLINE FORM-I OF LINEZOLID, SUBSTANTIALLY FREE OF RESIDUAL SOLVENT CYP2C9, CYP2F1, CYP2C19 F10 2944/4885GRM2 3278/4885MAOA 1712/4885
US-20060111350-A1 Solid forms of linezolid and processes for preparation thereof F9, Q6ZSR9, TBCD F10 46/4885GRM2 3845/4885MAOA 1756/4885
US-20150025236-A1 PROCESS FOR THE PREPARATION OF STABLE CRYSTALLINE FORM-I OF LINEZOLID, SUBSTANTIALLY FREE OF RESIDUAL SOLVENT CYP2C9, CYP2C19, CYP2F1 F10 2680/4885GRM2 3474/4885MAOA 1539/4885
US-20060252932-A1 Isolated bis-linezolid, preparation thereof, and its use as a reference standard FHIT, CYP2C9, CYP2C19 F10 3494/4885GRM2 3631/4885MAOA 2591/4885
US-20050192275-A1 Novel antimycobacterial compounds MDH1, IMMT, MLYCD F10 4391/4885GRM2 4031/4885MAOA 2058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.